Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/232527
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in Chronic Myeloid Leukemia |
Autor: | Contreras Mostazo, Miriam G.; Kurrle, Nina; Casado, Marta CSIC ORCID ; Fuhrmann, Dominik; Alshamleh, Islam; Häupl, Björn; Martín-Sanz, Paloma CSIC ORCID ; Brüne, Bernhard; Serve, Hubert; Schwalbe, Harald; Schnütgen, Frank; Marín, Silvia; Cascante, Marta CSIC ORCID | Palabras clave: | Tyrosine kinase inhibitors Chronic myeloid leukemia Metabolic reprogramming Proteomics |
Fecha de publicación: | 2020 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Cancers 12(11): 3443 (2020) | Resumen: | Tyrosine kinase inhibitors (TKIs) are currently the standard chemotherapeutic agents for the treatment of chronic myeloid leukemia (CML). However, due to TKI resistance acquisition in CML patients, identification of new vulnerabilities is urgently required for a sustained response to therapy. In this study, we have investigated metabolic reprogramming induced by TKIs independent of BCR-ABL1 alterations. Proteomics and metabolomics profiling of imatinib-resistant CML cells (ImaR) was performed. KU812 ImaR cells enhanced pentose phosphate pathway, glycogen synthesis, serine-glycine-one-carbon metabolism, proline synthesis and mitochondrial respiration compared with their respective syngeneic parental counterparts. Moreover, the fact that only 36% of the main carbon sources were utilized for mitochondrial respiration pointed to glycerol-phosphate shuttle as mainly contributors to mitochondrial respiration. In conclusion, CML cells that acquire TKIs resistance present a severe metabolic reprogramming associated with an increase in metabolic plasticity needed to overcome TKI-induced cell death. Moreover, this study unveils that KU812 Parental and ImaR cells viability can be targeted with metabolic inhibitors paving the way to propose novel and promising therapeutic opportunities to overcome TKI resistance in CML. | Descripción: | © 2020 by the authors. | Versión del editor: | http://dx.doi.org/10.3390/cancers12113443 | URI: | http://hdl.handle.net/10261/232527 | DOI: | 10.3390/cancers12113443 | E-ISSN: | 2072-6694 |
Aparece en las colecciones: | (IIBM) Artículos (IBV) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Metabolic_Contreras_PV_Art2020.pdf | 7,37 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
4
checked on 22-abr-2024
SCOPUSTM
Citations
7
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
7
checked on 27-feb-2024
Page view(s)
105
checked on 24-abr-2024
Download(s)
107
checked on 24-abr-2024